

Rosalyn Jane Hithersay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2245609/publications.pdf>

Version: 2024-02-01

19
papers

925
citations

623734

14
h-index

940533

16
g-index

23
all docs

23
docs citations

23
times ranked

1352
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2021, 26, 5766-5788.	7.9	63
2	Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, 595-604.	0.8	16
3	The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer's Disease in Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 1882.	2.4	14
4	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	10.2	29
5	Differential Associations of Apolipoprotein E ϵ 4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome. <i>JAMA Network Open</i> , 2020, 3, e2018221.	5.9	7
6	Health comorbidities and cognitive abilities across the lifespan in Down syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 4.	3.1	85
7	Reply to "Down Syndrome Cognitive Marker's Significance in Alzheimer's Disease and Dementia Management". <i>Alzheimer's and Dementia</i> , 2019, 15, 1238-1239.	0.8	0
8	Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome. <i>Frontiers in Psychiatry</i> , 2019, 10, 158.	2.6	18
9	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26.	6.2	56
10	Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. <i>JAMA Neurology</i> , 2019, 76, 152.	9.0	110
11	Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2019, 15, 245-257.	0.8	68
12	O1802: SEQUENCE OF COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME DURING PROGRESSION FROM PRECLINICAL TO PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P235.	0.8	0
13	Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 741-751.	3.7	64
14	Cognitive decline and dementia in Down syndrome. <i>Current Opinion in Psychiatry</i> , 2017, 30, 102-107.	6.3	54
15	[P3328]: USING FUNCTIONAL NEAR INFRARED SPECTROSCOPY (FNIRS) TO MEASURE FRONTAL CORTICAL ACTIVITY IN ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2017, 13, P1076.	0.8	0
16	The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. <i>Wellcome Open Research</i> , 2016, 1, 11.	1.8	55
17	Carer-led health interventions to monitor, promote and improve the health of adults with intellectual disabilities in the community: A systematic review. <i>Research in Developmental Disabilities</i> , 2014, 35, 887-907.	2.2	26
18	Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. <i>Lancet Psychiatry</i> , the, 2014, 1, 522-530.	7.4	58

#	ARTICLE	IF	CITATIONS
19	Transfer of Cognitive Training across Magnitude Dimensions Achieved with Concurrent Brain Stimulation of the Parietal Lobe. <i>Journal of Neuroscience</i> , 2013, 33, 14899-14907.	3.6	196